ES2808978T8 - Heteroarilamidas como inhibidores de la agregación de proteínas - Google Patents

Heteroarilamidas como inhibidores de la agregación de proteínas

Info

Publication number
ES2808978T8
ES2808978T8 ES18156929T ES18156929T ES2808978T8 ES 2808978 T8 ES2808978 T8 ES 2808978T8 ES 18156929 T ES18156929 T ES 18156929T ES 18156929 T ES18156929 T ES 18156929T ES 2808978 T8 ES2808978 T8 ES 2808978T8
Authority
ES
Spain
Prior art keywords
heteroarylamides
inhibitors
protein aggregation
aggregation
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18156929T
Other languages
English (en)
Other versions
ES2808978T3 (es
Inventor
Emily M Stocking
Wolfgang Wrasidlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2808978(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Application granted granted Critical
Publication of ES2808978T3 publication Critical patent/ES2808978T3/es
Publication of ES2808978T8 publication Critical patent/ES2808978T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18156929T 2014-01-29 2015-01-28 Heteroarilamidas como inhibidores de la agregación de proteínas Active ES2808978T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12

Publications (2)

Publication Number Publication Date
ES2808978T3 ES2808978T3 (es) 2021-03-02
ES2808978T8 true ES2808978T8 (es) 2021-03-22

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15705417.2T Active ES2675301T3 (es) 2014-01-29 2015-01-28 Heteroarilamidas como inhibidores de la agregación de proteínas
ES18156929T Active ES2808978T3 (es) 2014-01-29 2015-01-28 Heteroarilamidas como inhibidores de la agregación de proteínas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15705417.2T Active ES2675301T3 (es) 2014-01-29 2015-01-28 Heteroarilamidas como inhibidores de la agregación de proteínas

Country Status (37)

Country Link
US (3) US9738635B2 (es)
EP (2) EP3348556B1 (es)
JP (2) JP6619741B2 (es)
KR (1) KR102383038B1 (es)
CN (2) CN111039939B (es)
AP (1) AP2016009347A0 (es)
AU (1) AU2015211119B2 (es)
BR (2) BR122018001892B1 (es)
CA (1) CA2937967C (es)
CL (1) CL2016001918A1 (es)
CR (1) CR20160394A (es)
CY (2) CY1120348T1 (es)
DK (2) DK3348556T3 (es)
EA (1) EA032374B1 (es)
EC (1) ECSP16070327A (es)
ES (2) ES2675301T3 (es)
HK (1) HK1231470A1 (es)
HR (2) HRP20180813T1 (es)
HU (2) HUE040274T2 (es)
IL (1) IL246987B (es)
LT (2) LT3348556T (es)
ME (1) ME03800B (es)
MX (1) MX2016009896A (es)
MY (1) MY187450A (es)
NZ (1) NZ722487A (es)
PE (1) PE20161393A1 (es)
PH (1) PH12016501493A1 (es)
PL (2) PL3348556T3 (es)
PT (2) PT3348556T (es)
RS (2) RS57533B1 (es)
SA (1) SA516371579B1 (es)
SG (1) SG11201606108RA (es)
SI (2) SI3099684T1 (es)
TR (1) TR201809440T4 (es)
UA (1) UA118209C2 (es)
WO (1) WO2015116663A1 (es)
ZA (1) ZA201605246B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3348556T3 (da) 2014-01-29 2020-08-03 UCB Biopharma SRL Heteroarylamider som hæmmere af proteinaggregering
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
US11091474B2 (en) * 2017-01-26 2021-08-17 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
MX2019007053A (es) * 2017-01-26 2019-08-29 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas.
WO2018138088A1 (en) * 2017-01-26 2018-08-02 Ucb Biopharma Sprl Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
AU2018265584B2 (en) * 2017-05-12 2023-09-28 Ludwig-Maximilians-Universität München Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
US11505528B2 (en) 2017-08-04 2022-11-22 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
WO2019089640A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2023125376A1 (zh) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
MXPA05005547A (es) * 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
ES2284081T3 (es) * 2003-12-19 2007-11-01 Bristol-Myers Squibb Company Heterociclos azabiciclicos como modulares de receptores canabinoides.
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
BRPI0513915A (pt) * 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
CA2580725A1 (en) * 2004-09-20 2006-03-30 4Sc Ag Novel heterocyclic nf-kb inhibitors
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
BRPI0615524A2 (pt) * 2005-07-11 2010-04-06 Devgen Nv derivados da amida como inibidores da quinase
EA016300B1 (ru) * 2005-07-29 2012-04-30 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
KR20080104147A (ko) * 2006-03-15 2008-12-01 4에스체 악티엔게젤샤프트 신규의 헤테로환 ＮＦ-κＢ 억제제
CA2668744C (en) * 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP2013508350A (ja) * 2009-10-20 2013-03-07 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
JP6159388B2 (ja) 2012-03-28 2017-07-05 ニューロポア セラピーズ，インコーポレイティド タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体
US9284309B2 (en) * 2012-07-16 2016-03-15 Neuropore Therapies, Inc. Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation
DK3348556T3 (da) 2014-01-29 2020-08-03 UCB Biopharma SRL Heteroarylamider som hæmmere af proteinaggregering
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
WO2018138088A1 (en) 2017-01-26 2018-08-02 Ucb Biopharma Sprl Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
MX2019007053A (es) 2017-01-26 2019-08-29 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas.

Also Published As

Publication number Publication date
SI3099684T1 (en) 2018-08-31
PH12016501493B1 (en) 2017-02-06
PL3348556T3 (pl) 2020-11-02
CY1120348T1 (el) 2019-07-10
PH12016501493A1 (en) 2017-02-06
DK3099684T3 (en) 2018-07-16
SI3348556T1 (sl) 2020-10-30
KR20160113287A (ko) 2016-09-28
US20160207912A1 (en) 2016-07-21
NZ722487A (en) 2022-04-29
AU2015211119A1 (en) 2016-08-11
JP6783900B2 (ja) 2020-11-11
BR122018001892B1 (pt) 2023-05-02
EP3099684A1 (en) 2016-12-07
AP2016009347A0 (en) 2016-07-31
DK3348556T3 (da) 2020-08-03
IL246987A0 (en) 2016-09-29
CA2937967C (en) 2022-07-26
JP2019163321A (ja) 2019-09-26
TR201809440T4 (tr) 2018-07-23
MX2016009896A (es) 2017-01-11
CL2016001918A1 (es) 2017-01-13
ECSP16070327A (es) 2018-05-31
US20190308965A1 (en) 2019-10-10
ZA201605246B (en) 2022-05-25
EP3099684B8 (en) 2018-07-04
CR20160394A (es) 2016-11-01
AU2015211119A8 (en) 2016-12-15
HUE040274T2 (hu) 2019-03-28
JP6619741B2 (ja) 2019-12-11
KR102383038B1 (ko) 2022-04-05
HRP20180813T1 (hr) 2018-07-27
EP3348556A1 (en) 2018-07-18
LT3348556T (lt) 2020-08-10
LT3099684T (lt) 2018-06-25
BR112016017344B1 (pt) 2023-05-16
RS60547B1 (sr) 2020-08-31
AU2015211119B2 (en) 2019-05-30
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
US11078196B2 (en) 2021-08-03
PL3099684T3 (pl) 2018-09-28
CN106132960B (zh) 2019-12-17
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
CN111039939A (zh) 2020-04-21
PT3348556T (pt) 2020-07-27
ME03800B (me) 2021-04-20
ES2808978T3 (es) 2021-03-02
HRP20201107T8 (hr) 2020-12-11
MY187450A (en) 2021-09-22
PE20161393A1 (es) 2017-01-08
EA201691529A1 (ru) 2017-01-30
CN106132960A (zh) 2016-11-16
CN111039939B (zh) 2023-09-19
EP3348556B1 (en) 2020-04-29
RS57533B1 (sr) 2018-10-31
CA2937967A1 (en) 2015-08-06
IL246987B (en) 2021-12-01
EP3099684B1 (en) 2018-04-04
SG11201606108RA (en) 2016-08-30
CY1123374T1 (el) 2021-12-31
HRP20201107T1 (hr) 2020-10-30
HUE050964T2 (hu) 2021-01-28
JP2017505779A (ja) 2017-02-23
WO2015116663A8 (en) 2016-09-15
BR112016017344A2 (pt) 2017-10-03
HK1231470A1 (zh) 2017-12-22
EA032374B1 (ru) 2019-05-31
PT3099684T (pt) 2018-10-22
SA516371579B1 (ar) 2019-07-16
US20180093979A1 (en) 2018-04-05
ES2675301T3 (es) 2018-07-10

Similar Documents

Publication Publication Date Title
CL2016002736A1 (es) Inhibidores de demetilasa-1 específico de lisina
ES2716415T3 (es) Espirocicloheptanos como inhibidores de ROCK
DK3169292T3 (da) Urinadsorberende tampon
ES2808978T8 (es) Heteroarilamidas como inhibidores de la agregación de proteínas
FR3018941B1 (fr) Pilotage de vehicules en convoi
DK3145946T3 (da) Bakteriebaseret proteintilførsel
DK3237432T3 (da) Proteinfremstilling
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3283210T3 (da) Fremgangsmåde
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3132009T3 (da) Fremgangsmåde
DK3099791T3 (da) Protein
DK3166473T3 (da) Oftalmoskoper
MA41266A (fr) Cataplasme
DK3099793T3 (da) Protein
FR3023290B1 (fr) Derives de flavaglines
CL2016001959A1 (es) Hexahidrofuropirroles como inhibidores de pde1
FR3024647B1 (fr) Transat de puericulture
DK3285588T3 (da) Fremgangsmåde
FR3024135B1 (fr) Piece de harnachement
DK3183264T3 (da) Pegyleringsfremgangsmåde
UA31206S (uk) Комплект етикеток
UA28942S (uk) Комплект етикеток